Urovant Sciences Ltd (UROV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 03/31
(Values in U.S. thousands)
| 03-2020 | 03-2019 | 03-2018 | 03-2017 | |
| Assets | ||||
| Current Assets | ||||
| Cash & Cash Equivalents | 51,657 | 85,596 | 7,194 | 4,768 |
| Receivables | 172 | N/A | N/A | N/A |
| TOTAL | $58,318 | $98,510 | $12,390 | $4,776 |
| Non-Current Assets | ||||
| PPE Net | 1,210 | 923 | 510 | N/A |
| Other Non-Current Assets | 3,767 | 688 | 84 | 0 |
| TOTAL | $4,977 | $1,611 | $594 | $N/A |
| Total Assets | $63,295 | $100,121 | $12,984 | $4,776 |
| Liabilities | ||||
| Current Liabilities | ||||
| Accounts payable and accrued liabilities | 1,589 | 1,925 | 833 | 16 |
| Accrued Expenses | 21,756 | 9,877 | 3,595 | 8 |
| Other current liabilities | 7,235 | 15 | 1,482 | 842 |
| TOTAL | $30,931 | $11,817 | $5,910 | $866 |
| Non-Current Liabilities | ||||
| Long Term Debt | 87,252 | 13,534 | N/A | N/A |
| Other Non-Current Liabilities | 3,118 | 0 | 0 | 0 |
| TOTAL | $90,370 | $13,534 | $N/A | $N/A |
| Total Liabilities | $121,301 | $25,351 | $5,910 | $866 |
| Shareholders' Equity | ||||
| Shares Outstanding, K | 30,799 | N/A | N/A | N/A |
| Retained earnings | -322,276 | -175,531 | -64,185 | -27,112 |
| Other shareholders' equity | 452 | 269 | -1,303 | -25 |
| TOTAL | $-58,006 | $74,770 | $7,074 | $3,910 |
| Total Liabilities And Equity | $63,295 | $100,121 | $12,984 | $4,776 |